Young Cell-Derived Vesicles Rebalance Bone and Fat in Aged Mice via a Thy1 Protein Signal
Vesicles from young stem cells restored bone and cut marrow fat in aged mice. The age-declining protein Thy1 drove the effect, pointing to engineered vesicle therapies.
Summary
As people age, bone marrow shifts toward fat and away from bone, raising fracture risk. Researchers examined apoptotic vesicles (apoVs), small membrane particles released by dying mesenchymal stem cells, from 1-week, 3-month and 18-month-old mice. Vesicle size and basic markers were similar across ages, but function and protein cargo differed. Young apoVs boosted bone formation and curbed fat formation in aged stem cells, and in aged mice they improved bone mass and reduced marrow and abdominal fat. Vesicles from old mice did nothing. The protein Thy1 declined steadily with donor age and appeared to mediate the benefit. Per the abstract, engineered Thy1-enriched apoVs worked through an ERK–TAZ signaling pathway. All evidence is from mice and cells.
Detailed Summary
Age-related bone loss is often paired with fat accumulation in the bone marrow, and higher marrow fat is linked to lower bone density and greater fracture risk. Bone marrow mesenchymal stem cells (MSCs) can become either bone-forming or fat-forming cells, and with age they tilt toward fat. Apoptotic vesicles (apoVs), released by MSCs as they die, can restore stem cell function in earlier work. But apoVs from different donors may not work equally well, which could explain inconsistent preclinical results.
The team compared apoVs from MSCs of 1-week, 3-month and 18-month-old C57BL/6J mice. The three groups looked alike physically: roughly 200 nm median size, about −25 mV zeta potential, phosphatidylserine-positive, and carrying standard EV and MSC-apoV markers. Their function differed sharply. In aged MSCs, which retain only about 30–40% of young osteogenic capacity, 1-week apoVs restored roughly 80%, 3-month apoVs about 60%, and 18-month apoVs almost none. Anti-adipogenic activity followed the same pattern. In 18-month-old mice given repeated intravenous apoVs for four months, young apoVs improved trabecular bone and reduced marrow fat, abdominal fat and fatty liver. 3-month apoVs gave intermediate benefits and 18-month apoVs gave none. Blood counts, biochemistry and organ examination showed no differences between groups, suggesting no overt toxicity. Labeled apoVs accumulated mainly in the liver, with increasing signal in the femur over 48 hours.
Proteomics identified more than 5,800 proteins per sample and showed that donor age substantially reshaped apoV cargo. Three proteins (Alpl, Fmo1, Maob) rose and three (Annexin A8, Thy1, Tppp3) fell with age. Thy1, a known MSC regulator that favors bone over fat differentiation, declined progressively in MSCs and in apoVs. Immunofluorescence showed Thy1-positive apoVs were taken up by MSCs within 6 hours, with signal peaking near 48 hours and localizing around the nucleus. This suggests recipient cells reuse the delivered Thy1. A pathway screen pointed to ERK signaling. Per the abstract, the downstream effector is TAZ, and Thy1 acts through a Thy1–ERK–TAZ axis. The abstract also reports that engineered Thy1-enriched apoVs, made by magnetic-activated sorting and protein corona modification, enhanced osteogenesis and suppressed adipogenesis. In aged mice they restored trabecular bone, reduced marrow fat and improved systemic lipid metabolism.
The work suggests that vesicle-based therapies should be matched to the donor's age and cargo. Thy1 could serve as a quality-control marker for apoV preparations. Caveats: the supplied text ends partway through the mechanistic results, so details of the Thy1 loss-of-function experiments, the ERK–TAZ analysis and the engineered-vesicle testing rest on the abstract. The data are from mice and cell culture, and the human relevance, durability and dosing remain untested.
Key Findings
- ApoVs from young mouse MSCs restored about 80% of aged MSC osteogenic capacity; 3-month apoVs restored about 60% and 18-month apoVs almost none.
- Four months of young apoV injections improved bone mass and reduced marrow fat, abdominal fat and fatty liver in 18-month-old mice, with no apparent toxicity.
- Proteomics of over 5,800 proteins showed donor age reshapes apoV cargo; Thy1 declined steadily with age and was linked to bone-promoting, anti-fat effects.
- Recipient MSCs internalized Thy1-positive apoVs within 6 hours, with signal peaking at about 48 hours and clustering near the nucleus.
- Per the abstract, engineered Thy1-enriched apoVs acted through a Thy1–ERK–TAZ axis and corrected bone-fat imbalance and lipid disorders in aged mice.
Methodology
Preclinical study comparing apoVs from MSCs of 1-week, 3-month and 18-month-old C57BL/6J mice, characterized physically and by mass spectrometry proteomics with western blot validation. Function was tested in aged MSC differentiation assays and in 18-month-old mice given repeated intravenous apoVs for four months, assessed by micro-CT, histology, biodistribution imaging and safety panels. The mechanistic and engineered-vesicle experiments were only partly available in the supplied text.
Study Limitations
All evidence comes from mouse models and cultured cells, with no human data, and sex, dose-response and long-term safety were not clearly addressed in the available text. The supplied full text is truncated before the detailed Thy1 functional validation, ERK–TAZ mechanism and engineered-apoV results, so those claims rest on the abstract. Thy1 may be one of several age-sensitive cargo proteins, and vesicles accumulated mainly in the liver, so systemic effects may not be bone-specific.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: